03.12.13
Broomfield, Colo.-based Lanx Inc. has gathered new data that suggests its Aspen MIS (minimally invasive surgery) fusion system is an appropriate, less-invasive approach to lumbar fusion, enabling solid fusion with improved post-operative outcomes and minimal complications.
“The presented studies continue to validate the Aspen system as a truly minimally invasive fusion device, and demonstrate that its benefits extend beyond the procedure to positive postoperative outcomes,” said Lanx CEO Dan Gladney. “This research, coupled with the clinical experience of hundreds of surgeons throughout the world, speaks to the versatility and efficacy of the Aspen device in meeting the needs of an aging and increasingly active population.”
The research was presented at the 29th Annual Meeting of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Disorders of the Spine and Peripheral Nerves, held March 6-9 in Phoenix, Ariz. The data presented covered the issue of blood loss as a quantitative qualifier for the term “minimally invasive” in a device; clinical outcomes and fusion rates after spinous process fixation in an elderly cohort; and change in sagittal plane (a vertical cross section of the body) alignment following single-level decompression and posterolateral lumbar fusion with aspen interspinous process.
According to Lanx, the Aspen system is currently being used in a range of surgical applications including posterior lumbar fusions and interbody fusions (posterior, transforaminal and anterior lumbar interbody fusion, and lateral) for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor.
“The presented studies continue to validate the Aspen system as a truly minimally invasive fusion device, and demonstrate that its benefits extend beyond the procedure to positive postoperative outcomes,” said Lanx CEO Dan Gladney. “This research, coupled with the clinical experience of hundreds of surgeons throughout the world, speaks to the versatility and efficacy of the Aspen device in meeting the needs of an aging and increasingly active population.”
The research was presented at the 29th Annual Meeting of the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Disorders of the Spine and Peripheral Nerves, held March 6-9 in Phoenix, Ariz. The data presented covered the issue of blood loss as a quantitative qualifier for the term “minimally invasive” in a device; clinical outcomes and fusion rates after spinous process fixation in an elderly cohort; and change in sagittal plane (a vertical cross section of the body) alignment following single-level decompression and posterolateral lumbar fusion with aspen interspinous process.
According to Lanx, the Aspen system is currently being used in a range of surgical applications including posterior lumbar fusions and interbody fusions (posterior, transforaminal and anterior lumbar interbody fusion, and lateral) for the treatment of degenerative disc disease, spondylolisthesis, spinal trauma or spinal tumor.